Zone IVb Stability Testing Explained: What Buyers in Hot & Humid Markets Need
Climatic zones, Zone IVb storage conditions, long-term vs accelerated studies, and the stability data buyers should request before registering medicines for hot and very humid markets.
A medicine that stays within specification for three years in a temperate climate may not do so in a hot, very humid one. That is why regulators divide the world into climatic zones and ask for stability data generated under the conditions of the market where the product will be sold. For many countries in Africa, South and Southeast Asia and Latin America, that means Zone IVb data. This guide explains what Zone IVb is, how stability studies are designed for it, and what buyers should check before registering a product.
What Are Climatic Zones?
Stability guidance from the ICH and WHO groups the world into climatic zones based on average temperature and humidity. The zone determines the storage conditions used in long-term stability studies.
Zones I and II cover temperate and subtropical climates. Zone III covers hot and dry climates. Zone IV is split into IVa (hot and humid) and IVb (hot and very humid).
Zone IVb was introduced in WHO guidance to reflect regions where humidity is consistently very high. Many ASEAN countries and a number of African and Latin American countries expect stability data at Zone IVb conditions for new registrations.
Zone IVb Storage Conditions
For Zone IVb, the standard long-term storage condition is 30°C ± 2°C at 75% RH ± 5% RH. Accelerated studies are commonly carried out at 40°C ± 2°C at 75% RH ± 5% RH.
Long-term data supports the shelf life that will be printed on the pack. Accelerated data helps predict behaviour under stress and can support a provisional shelf life while long-term studies continue, where the importing authority allows this.
By comparison, Zone II long-term studies are typically run at 25°C / 60% RH. Data generated only at Zone II conditions is generally not sufficient for a Zone IVb market.
Why Humidity Matters So Much
Moisture can affect many dosage forms. Tablets may soften, harden or change dissolution behaviour. Capsule shells can become brittle or sticky. Effervescent products and dry powders are especially sensitive because moisture can trigger reactions before use.
Chemically, some active ingredients degrade faster in the presence of moisture and heat, increasing impurity levels over time.
This is why packaging is part of stability, not separate from it. The same formulation may pass in an Alu-Alu blister and fail in a PVC blister or a bottle without desiccant.
What a Typical Stability Programme Includes
A stability study for registration usually covers:
- Batches: Commonly three primary batches, manufactured by a process representative of commercial production.
- Packaging: The same container-closure system proposed for the market.
- Time points: For long-term studies, typically 0, 3, 6, 9, 12, 18, 24 and 36 months; for accelerated studies, typically 0, 3 and 6 months.
- Tests: Appearance, assay, related substances (impurities), dissolution or disintegration where relevant, water content and microbiological quality where relevant.
- Evaluation: Statistical or trend analysis of the results to justify the proposed shelf life and storage statement.
What Buyers Should Check Before Registration
Before submitting a product in a Zone IVb market, buyers should review the stability section of the dossier rather than relying on a summary statement. Useful questions include:
- Were long-term studies carried out at 30°C / 75% RH, and for how many months of data?
- Does the packaging in the study match the pack you plan to sell?
- Does the proposed shelf life match the length of long-term data available?
- Is the storage statement on the label consistent with the data (for example, 'Store below 30°C, protect from moisture')?
- Are any trends in impurities or dissolution explained and within specification?
Common Pitfalls
Registrations are often queried when the packaging changes after the stability study was completed, when the shelf life claimed is longer than the data supports, or when stability was run at Zone II conditions only.
Another frequent issue is a mismatch between the storage statement in the dossier and the one printed on artwork. Aligning these early avoids re-printing packaging material.
Zelnex and Zone IVb Markets
Zelnex Pharmaceuticals supplies WHO-GMP formulations and CTD/eCTD dossiers to buyers in hot and humid markets. When you request a quote, tell us your target country and preferred pack format, and our regulatory desk will confirm the stability data available for each product.
Explore dosage forms and molecules on our Products page, see our regulatory support on the Services page, or contact the export desk to discuss your requirements. For the certificates that accompany a registration file, read COPP, Free Sale Certificate, GMP Certificate & COA explained.
More Technical Regulatory Insights
Understanding CTD & eCTD for Pharmaceutical Market Registration
A complete guide to Common Technical Document (CTD) and electronic CTD (eCTD) structures, Module 1–5 organization, and international regulatory registration strategies.
WHO-GMP in Pharmaceutical Manufacturing: What Buyers Should Know
Essential insights into Good Manufacturing Practice (GMP), quality systems, analytical controls, documentation audits, and evaluating pharmaceutical manufacturing partners.